Singapore -
English -
HSA (Health Sciences Authority)
havrix junior vaccine 720 elisa units0.5 ml
glaxosmithkline pte ltd - hepatitis a virus inactivated - injection - 720 elisa units/0.5ml - hepatitis a virus inactivated 720 elisa units/0.5ml
Singapore -
English -
HSA (Health Sciences Authority)
havrix 1440 vaccine 1440 elisa unitsml
glaxosmithkline pte ltd - hepatitis a virus (inactivated) - injection - 1440 elisa units/ml - hepatitis a virus (inactivated) 1440 elisa units/ml
Singapore -
English -
HSA (Health Sciences Authority)
merieux inactivated rabies vaccine
sanofi-aventis singapore pte. ltd. - rabies virus (wistar rabies pm/wi 38-1503-3m strain) - injection, powder, for solution - min 2.5 iu/vial
Malta -
English -
Medicines Authority
tetavax, suspension for injection in multidose presentation, adsorbed tetanus vaccine
sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid - suspension for injection - tetanus toxoid 40 iu - vaccines
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
havrix 1440 suspension for injection
glaxosmithkline biologicals s.a. - hepatitis a vaccine inactivated - suspension for injection - 1440 elisa u/ml
Sweden -
English -
Läkemedelsverket (Medical Products Agency)
viatim suspension och vätska till injektionsvätska, suspension, förfylld spruta
Singapore -
English -
HSA (Health Sciences Authority)
cerezyme® (imiglucerase) 400u powder for solution for injection
sanofi-aventis singapore pte. ltd. - imiglucerase - injection, powder, for solution - 424 u - imiglucerase 424 u
European Union -
English -
EMA (European Medicines Agency)
cerezyme
sanofi b.v. - imiglucerase - gaucher disease - other alimentary tract and metabolism products, - cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (type 1) or chronic neuronopathic (type 3) gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. the non-neurological manifestations of gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencythrombocytopeniabone disease after exclusion of other causes such as vitamin d deficiencyhepatomegaly or splenomegaly
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
cerezyme 400unit powder for solution for infusion vials
genzyme therapeutics ltd - imiglucerase - powder for solution for infusion - 400unit
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
revolade
glaxo wellcome s.a. - eltrombopag (eltrombopag olamine) - tablets film-coated - 25mg